VYGR

EX-99.1

2 vygr-20260507xex99d1.htm

EX-99.1

EXHIBIT 99.1

Voyager Reports First Quarter 2026 Financial and Operating Results

​

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 -

​

- Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data -

​

- Ended Q1 2026 with cash position of $172 million, runway into 2028 -

​

LEXINGTON, Mass., May 7, 2026 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2026 financial and operating results.

​

“As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager looks forward to third-party data in mid-2026 that have the potential to confirm tau knockdown as the next critical approach to treating Alzheimer’s disease. Then, in the second half of the year, we expect first-in-human dosing of our tau silencing gene therapy VY1706 and tau PET imaging efficacy data for our anti-tau antibody VY7523,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “With our strong cash position of $172 million that is expected to provide runway into 2028, we continue to execute across our pipeline and platforms.”

​

First Quarter 2026 and Recent Highlights

●Pipeline updates:

oVY1706 (tau silencing gene therapy): Voyager completed investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology in Q1 2026. The U.S. Food and Drug Administration (FDA) IND application process is on track for Q2 2026 to support projected first-in-human dosing in Alzheimer’s disease (AD) patients in H2 2026.

oVY7523 (anti-tau antibody): Voyager continues to expect tau positron emission tomography (PET) imaging efficacy data in H2 2026 from the ongoing multiple ascending dose (MAD) clinical trial in AD patients.

●Neurocrine partnership update: Neurocrine completed GLP toxicology with NBIB-‘223 for Friedreich’s ataxia (FA) and received FDA orphan drug designation. Neurocrine has stated that it intends to initiate a clinical trial with NBIB-‘223 in H2 2026, pending successful FDA IND clearance.

●Multiple abstracts accepted for presentation at ASGCT 2026: Voyager will make multiple presentations at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 29th Annual Meeting, including a late-breaking oral presentation on 3-month GLP toxicology data for VY1706, an oral presentation on directed evolution of Voyager’s muscular and neuromuscular capsid variants in mice and non-human primates, and multiple poster presentations.

●Posters on AD programs presented at AD/PD™ 2026: Preclinical data were shared for VY1706, as well as for Voyager’s approach to modulate the expression of APOE4, the strongest genetic risk factor for AD.

​

Anticipated Upcoming 2026 Milestones

●Mid-Year: Third-party data that could significantly derisk tau knockdown hypothesis in AD

●H2: VY1706 expected to achieve first-in-human dosing in AD

●H2: Tau PET imaging data expected in MAD clinical trial of VY7523 in AD

●H2: Neurocrine intends to initiate a clinical trial with NBIB-‘223 for FA, pending successful FDA IND clearance

​

Financial Results

●Collaboration Revenues: Collaboration revenue was $2.6 million for the three months ended March 31, 2026, compared to $6.5 million for the first quarter of 2025. The decrease was primarily attributable to revenue recognized under our Neurocrine and Novartis collaboration agreements in the prior period as the collaborations mature beyond research.

●Research and Development Expenses: Research and development expenses were $24.6 million for the first quarter of 2026, compared to $31.5 million for the first quarter of 2025. The decrease was primarily due to cost-cutting and efficiency initiatives, partially offset by an increase in costs related to the tau silencing gene therapy program (VY1706) advancing towards planned clinical trials.

●General and Administrative Expenses: General and administrative expenses were $8.3 million for the first quarter of 2026, compared to $9.6 million for the first quarter of 2025. The decrease was primarily attributable to cost-cutting and efficiency initiatives year-over-year.

●Net Loss: Net loss was $27.9 million for the first quarter of 2026, compared to $31.0 million for the first quarter of 2025.

●Cash and Cash Equivalents: Cash, cash equivalents and marketable securities as of March 31, 2026, were $171.7 million. Based on Voyager’s current operating plans, the company expects its cash, cash equivalents, and marketable securities, along with anticipated collaboration reimbursements for work performed and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2028.

​

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course

Voyager Therapeutics, Inc._March 9, 2026 0001640266false00016402662026-03-092026-03-09 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 ​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ​ Date of Report (Date of Earliest Event Reported): March 9, 2026

Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter)

​ ​

​

​

​

​

Delaware ​ 001-37625 ​ 46-3003182

(State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (I.R.S. Employer Identification No.)

​ ​

​

​

75 Hayden Avenue Lexington, Massachusetts ​ 02421

(Address of principal executive offices) ​ (Zip Code)

​ Registrant’s telephone number, including area code (857) 259-5340 Not Applicable (Former name, former address and former fiscal year, if changed since last report) ​

​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​ ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value

VYGR

Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​

​ ​

Item 2.02. Results of Operations and Financial Condition. On March 9, 2026, Voyager Therapeutics, Inc. (the “Company”) announced fourth quarter and full year 2025 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. ​ The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01. Financial Statements and Exhibits (d)    Exhibits ​ The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: ​ ​

​

​

Exhibit No. ​ Description

​ ​ ​

99.1 ​ Press release dated March 9, 2026 entitled “Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results”.

104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

​ ​ ​

​ ​

2

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​ ar

​

​

Date: March 9, 2026

VOYAGER THERAPEUTICS, INC.

​ ​

​ By: /s/ Alfred Sandrock, M.D., Ph.D.

​ ​ Alfred Sandrock, M.D., Ph.D.

​ ​ Chief Executive Officer, President, and Director (Principal Executive Officer)

​ ​ ​ ​ ​ ​ ​ ​

3

Voyager Therapeutics, Inc._November 10, 2025 0001640266false00016402662025-11-102025-11-10 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 ​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ​ Date of Report (Date of Earliest Event Reported): November 10, 2025

Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter)

​ ​

​

​

​

​

Delaware ​ 001-37625 ​ 46-3003182

(State or other jurisdiction of incorporation) ​ (Commission File Number) ​ (I.R.S. Employer Identification No.)

​ ​

​

​

75 Hayden Avenue Lexington, Massachusetts ​ 02421

(Address of principal executive offices) ​ (Zip Code)

​ Registrant’s telephone number, including area code (857) 259-5340 ​

​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​ ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value

VYGR

Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​

​ ​

Item 2.02. Results of Operations and Financial Condition. On November 10, 2025, Voyager Therapeutics, Inc. (the “Company”) announced third quarter 2025 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. ​ The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01. Financial Statements and Exhibits (d)    Exhibits ​ The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: ​ ​

​

​

Exhibit No. ​ Description

​ ​ ​

99.1 ​ Press release dated November 10, 2025 entitled “Voyager Reports Third Quarter 2025 Financial and Operating Results”.

104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

​ ​ ​

​ ​

2

SIGNATURES

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​ ar

​

​

Date: November 10, 2025

VOYAGER THERAPEUTICS, INC.

​ ​

​ By: /s/ Alfred Sandrock, M.D., Ph.D.

​ ​ Alfred Sandrock, M.D., Ph.D.

​ ​ Chief Executive Officer, President, and Director (Principal Executive Officer)

​ ​ ​ ​ ​ ​ ​ ​

3